Clinical Trials Directory

Trials / Unknown

UnknownNCT01162941

Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
38 (estimated)
Sponsor
Cooperative Study Group A for Hematology · Network
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Proportion who would avoid splenectomy at 6 months of follow up

Detailed description

1. If urea breath test (+); omeprazole 20mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 1 week. Second line Helicobacter pylori eradication will be permitted after failure of first line treatment. 2. Anti-D Anti-Ro 50 μg/kg IV for 2 days (D1, 2) 3. Danazol maintenance (from D1): Danazol will be continued at least 3 months. The dose of danazol can be reduced according to the adverse effects, especially in premenopausal women.

Conditions

Interventions

TypeNameDescription
OTHERSteroid refractory ITPa platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)

Timeline

Start date
2010-02-01
Primary completion
2011-07-01
Completion
2012-01-01
First posted
2010-07-15
Last updated
2010-07-15

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01162941. Inclusion in this directory is not an endorsement.

Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Th (NCT01162941) · Clinical Trials Directory